Stock Research: Pulmonx

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Pulmonx

NSQ:LUNG US7458481014
44
  • Value
    80
  • Growth
    5
  • Safety
    Safety
    72
  • Combined
    56
  • Sentiment
    29
  • 360° View
    360° View
    44
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 53 40 21
Growth
5 39 79 43
Safety
Safety
72 44 47 52
Sentiment
29 29 75 26
360° View
360° View
44 36 85 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
27 44 91 62
Opinions Change
50 50 50 50
Pro Holdings
n/a 41 49 24
Market Pulse
34 38 56 31
Sentiment
29 29 75 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 53 40 21
Growth
5 39 79 43
Safety Safety
72 44 47 52
Combined
56 36 67 22
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
84 51 22 11
Price vs. Earnings (P/E)
18 18 18 18
Price vs. Book (P/B)
88 63 56 48
Dividend Yield
1 1 1 1
Value
80 53 40 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
17 79 62 87
Profit Growth
21 34 26 20
Capital Growth
63 48 91 79
Stock Returns
3 17 89 17
Growth
5 39 79 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
53 49 58 63
Refinancing
94 78 65 59
Liquidity
14 16 20 26
Safety Safety
72 44 47 52

Similar Stocks

Discover high‑ranked alternatives to Pulmonx and broaden your portfolio horizons.

Sandisk

NSQ:SNDK
Country: USA
Industry: Technology Hardware & Peripherals
Size: X-Large
Full Stock Analysis

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Micron

NSQ:MU
Country: USA
Industry: Semiconductors
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This stock is a good value with safe financing, but has low growth and negative sentiment. It is a good option for a cautious value investor looking for stability but who can tolerate low momentum and skeptical professional opinion.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: